down arrow

Deep Medicine Acquisition Corp.

  • Market Cap: Micro Cap
  • Industry: Finance
  • ISIN: US2437331026
USD
1.17
-0.01 (-0.85%)

Dec 05

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.151.20

52 Week

0.128.50
Valuation
Technical
Day's Volume

CASH

10.18 k

Shareholding (Mar 2025)

FII

0.46%

Held by 4 FIIs

DII

98.8%

Held by 1 DIIs

Promoter

0.00%

What does Deep Medicine Acquisition Corp. do?

22-Jun-2025

Deep Medicine Acquisition Corp. is a micro-cap finance company with recent net sales of $5 million and a net loss of $3 million. It has a market cap of $4.61 million and does not pay dividends.

Overview:<BR>Deep Medicine Acquisition Corp. operates in the finance industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 5 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 4.61 Million <BR>Category: Micro Cap<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -999,999.00 <BR>Return on Equity: 195.59% <BR>Price to Book: -1.01<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Read More

Should I buy, sell or hold Deep Medicine Acquisition Corp.?

22-Jun-2025

Is Deep Medicine Acquisition Corp. overvalued or undervalued?

20-Sep-2025

As of May 10, 2024, Deep Medicine Acquisition Corp. is rated as risky due to its negative P/E ratio, a Price to Book Value of -1.36, and an EV to EBITDA ratio of -5.76, indicating overvaluation and financial distress despite a strong year-to-date return of 384.06%, which is unsustainable compared to the S&P 500's 12.22% return.

As of 10 May 2024, the valuation grade for Deep Medicine Acquisition Corp. has moved from does not qualify to risky. The company appears to be overvalued given its negative P/E ratio and a Price to Book Value of -1.36, indicating significant financial distress. Additionally, the EV to EBITDA ratio stands at -5.76, further highlighting the company's challenges in generating positive earnings.<BR><BR>In comparison to its peers, Deep Medicine Acquisition Corp. has a notably lower EV to EBITDA ratio than Blockchain Coinvestors Acquisition Corp. I, which is at -71.9007, and a much worse P/E ratio than Arisz Acquisition Corp., which is at -107.4237. Despite a strong year-to-date return of 384.06%, the company's recent performance has lagged behind the S&P 500, which returned 12.22% in the same period, suggesting that the stock's high returns may not be sustainable given its current valuation metrics.

Read More

Is Deep Medicine Acquisition Corp. technically bullish or bearish?

20-Sep-2025

As of August 6, 2025, Deep Medicine Acquisition Corp. shows a mildly bullish trend, supported by daily moving averages, but with caution due to bearish RSI signals and mixed indicators from weekly MACD and Dow Theory, despite a strong year-to-date performance of 384.06% compared to the S&P 500's 12.22%.

As of 6 August 2025, the technical trend for Deep Medicine Acquisition Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while the weekly MACD and Dow Theory show mildly bearish signals. The RSI is bearish across both weekly and monthly time frames, which adds some caution. Despite recent weakness, the stock has significantly outperformed the S&P 500 year-to-date with a return of 384.06% compared to the S&P 500's 12.22%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

With a Negative Book Value, the company has a Weak Long Term Fundamental Strength

  • Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0.00% over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2

Negative results in Mar 25

3

Risky - Negative EBITDA

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Finance

stock-summary
Market cap

USD 4 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-999,999.00

stock-summary
Return on Equity

195.59%

stock-summary
Price to Book

-0.81

Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-66.57%
0%
-66.57%
6 Months
397.87%
0%
397.87%
1 Year
170.83%
0%
170.83%
2 Years
-89.87%
0%
-89.87%
3 Years
-88.54%
0%
-88.54%
4 Years
-88.12%
0%
-88.12%
5 Years
0%
0%
0.0%

Deep Medicine Acquisition Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Deep Medicine Acquisition Corp. technically bullish or bearish?

As of 6 August 2025, the technical trend for Deep Medicine Acquisition Corp. has changed from bullish to mildly bullish. The current stance is mildly bullish, driven by daily moving averages indicating mild bullishness, while the weekly MACD and Dow Theory show mildly bearish signals. The RSI is bearish across both weekly and monthly time frames, which adds some caution. Despite recent weakness, the stock has significantly outperformed the S&P 500 year-to-date with a return of 384.06% compared to the S&P 500's 12.22%....

Read More

Is Deep Medicine Acquisition Corp. overvalued or undervalued?

As of 10 May 2024, the valuation grade for Deep Medicine Acquisition Corp. has moved from does not qualify to risky. The company appears to be overvalued given its negative P/E ratio and a Price to Book Value of -1.36, indicating significant financial distress. Additionally, the EV to EBITDA ratio stands at -5.76, further highlighting the company's challenges in generating positive earnings. In comparison to its peers, Deep Medicine Acquisition Corp. has a notably lower EV to EBITDA ratio than Blockchain Coinvestors Acquisition Corp. I, which is at -71.9007, and a much worse P/E ratio than Arisz Acquisition Corp., which is at -107.4237. Despite a strong year-to-date return of 384.06%, the company's recent performance has lagged behind the S&P 500, which returned 12.22% in the same period, suggesting that the stock's high returns may not be sustainable given its current valuation metrics....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-0.30
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
4.55%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.36
EV to EBIT
-4.18
EV to EBITDA
-5.76
EV to Capital Employed
-4.46
EV to Sales
0.40
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 2 Schemes (0.74%)

Foreign Institutions

Held by 4 Foreign Institutions (0.46%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 10.26% vs 0.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -106.25% vs -433.33% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.30",
          "val2": "3.90",
          "chgp": "10.26%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.40",
          "val2": "-0.60",
          "chgp": "-133.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.50",
          "val2": "0.80",
          "chgp": "87.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.30",
          "val2": "-1.60",
          "chgp": "-106.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-433.80%",
          "val2": "-202.70%",
          "chgp": "-23.11%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "Not Applicable: The company has declared_date for only one period",
        "dir": 0
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "21.90",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.50",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Interest",
          "val1": "6.90",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.80",
          "val2": "0.00",
          "chgp": "NA",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-96.20%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
4.30
3.90
10.26%
Operating Profit (PBDIT) excl Other Income
-1.40
-0.60
-133.33%
Interest
1.50
0.80
87.50%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.30
-1.60
-106.25%
Operating Profit Margin (Excl OI)
-433.80%
-202.70%
-23.11%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 10.26% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -106.25% vs -433.33% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Change(%)
Net Sales
21.90
0.00
NA
Operating Profit (PBDIT) excl Other Income
-1.50
0.00
NA
Interest
6.90
0.00
NA
Exceptional Items
0.10
0.00
NA
Consolidate Net Profit
-8.80
0.00
NA
Operating Profit Margin (Excl OI)
-96.20%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

Not Applicable: The company has declared_date for only one period

Consolidated Net Profit

Not Applicable: The company has declared_date for only one period

All Annual Resultsstock-summary
stock-summaryCompany CV
About Deep Medicine Acquisition Corp. stock-summary
stock-summary
Deep Medicine Acquisition Corp.
Finance
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."